Synthorx initiated with a Buy at H.C. Wainwright. H.C. Wainwright analyst Debjit Chattopadhyay started Synthorx with a Buy rating and $30 price target. The company’s Expanded Genetic Alphabet technology gives it the ability to manipulate the innate biological interaction of cytokines and adapt them to applications either in oncology or autoimmune diseases, “expanding the versatility and scope of the platform,” says the analyst.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.